| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/05/2005 | CN1560249A Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 01/05/2005 | CN1560080A Corpuscles of stannius protein, stanniocalcin |
| 01/05/2005 | CN1560051A 取代吡唑化合物 A substituted pyrazole compound |
| 01/05/2005 | CN1560041A Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 01/05/2005 | CN1559583A Applicaton of medicine for garlic oil anti radiation indnced aleucocytosis and DNA injury |
| 01/05/2005 | CN1559539A Medicinal mixture possessing alpha glycocidase inhibiting activity and its use |
| 01/05/2005 | CN1559492A Medicinal substance for antibrain senile extracted from schisandra |
| 01/05/2005 | CN1559420A Medicne tablets with function of delaying senility, and prepn. method therefor |
| 01/05/2005 | CN1559402A Novel use of Brazil Hematine red |
| 01/05/2005 | CN1183156C Heterocyclic compounds, intermediates thereof and elastase inhibitors |
| 01/05/2005 | CN1183136C Indoloquinazolinones |
| 01/05/2005 | CN1183134C Tricyclic vasporessin agonists |
| 01/05/2005 | CN1183132C Tetracyclic azepinoindole compounds as 5-HT receptor ligands |
| 01/05/2005 | CN1183129C Condensed azepines as vasporession agonists |
| 01/05/2005 | CN1183128C N-(heterocyclic)-benzene or pyridine sulphozmides as antithrombotic agents and anticoagulants |
| 01/05/2005 | CN1183122C Dipeptide nitrile cathepsin K inhibitors |
| 01/05/2005 | CN1183119C Arylpiperzines as metalloproteinase inhibiting agents (MMP) and their use |
| 01/05/2005 | CN1183113C Tri-aryl acid derivatives as PPAR receptor ligands |
| 01/05/2005 | CN1183112C PEG-inerferon conjugate |
| 01/05/2005 | CN1183107C Alkynyl containing hydroxamic acid compounds as TACE inhibitors |
| 01/05/2005 | CN1182857C Pollen Chinese medicine compound for enhancing motor ability |
| 01/04/2005 | US6838584 Estrogen receptor modulators |
| 01/04/2005 | US6838580 Opioid derivative |
| 01/04/2005 | US6838559 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease |
| 01/04/2005 | US6838547 Acryloyl derivatives of distamycin conjugated with glutathione; have antitumor activity and are thus useful in therapy in the treatment of cancer |
| 01/04/2005 | US6838481 Blocking melanin biosynthesis; side effect reduction |
| 01/04/2005 | US6838479 Amidine inhibitors of serine proteases |
| 01/04/2005 | US6838476 Imidazoles with anti-inflammatory activity |
| 01/04/2005 | US6838475 For prophylaxis and therapy of one or more symptoms of hepatitis C |
| 01/04/2005 | US6838474 Prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. This invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and |
| 01/04/2005 | US6838472 Substituted urea retinoid agonists |
| 01/04/2005 | US6838471 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| 01/04/2005 | US6838469 Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity |
| 01/04/2005 | US6838468 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 01/04/2005 | US6838467 Dosing regimen |
| 01/04/2005 | US6838465 N-acyltetrahydroisoquinoline derivatives |
| 01/04/2005 | US6838464 Inhibitor of cyclin-dependent kinase |
| 01/04/2005 | US6838460 Substituted phenylamidines medicaments containing said compounds and method for production thereof |
| 01/04/2005 | US6838459 7-alkyl-and cycloalkyl-substituted imidazotriazinones |
| 01/04/2005 | US6838458 5-(alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 01/04/2005 | US6838456 Condensed pyridoindole derivatives |
| 01/04/2005 | US6838454 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 01/04/2005 | US6838446 Anticancer agents; genetic engineered enzyme |
| 01/04/2005 | US6838442 Administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; administering jointly effective amount of an retinoid-X receptor modulator for therapy of diabetes or Syndrome X |
| 01/04/2005 | US6838439 Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists |
| 01/04/2005 | US6838428 A non-human mammal phenotype, vectors expressing the protein for treating respiratory system disease, viral diseases, purifying SP-D antibodies, enzyme inhibitor of metalloproteinase |
| 01/04/2005 | US6838269 Comprises reduced allergenic variant of enzymatic polypeptide for use in textile treatment and cleaning composition and animal feeds; antiallergens |
| 01/04/2005 | CA2340999C 5-arylindole derivatives |
| 01/04/2005 | CA2301503C Pharmaceutical compositions for oral administration of molecular iodine |
| 01/04/2005 | CA2288341C Erythropoietin in the treatment of domestic and livestock animals for anemia |
| 01/04/2005 | CA2250929C 4-[(thien-2-yl)methyl]imidazole derivatives having alpha2-adrenoceptor agonistic activity |
| 01/04/2005 | CA2242015C New chromene derivatives, the procedure for preparing them and the pharmaceutical compounds that contain them |
| 01/01/2005 | CA2472846A1 Methods for assessing and treating leukemia |
| 12/30/2004 | US20040268426 P2Y4 receptor transgenic and knockout non-human mammals |
| 12/30/2004 | US20040268425 use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms |
| 12/30/2004 | US20040267028 Such as 2-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride |
| 12/30/2004 | US20040267016 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 12/30/2004 | US20040267015 Bactericides |
| 12/30/2004 | US20040267012 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 12/30/2004 | US20040267010 For therapy of central nervous system disorders |
| 12/30/2004 | US20040267004 nucleic acid that binds to high mobility group protein-I (HMG-I), and causes presenilin-2 gene exon 5-lacked type aberrant splicing by the association with the HMG-I protein; an inhibitor for inhibiting a binding between protein-nucleic acid caused by aberrant splicing; drug screening; antisense agents |
| 12/30/2004 | US20040267003 Nucleotide and amino aicd sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro |
| 12/30/2004 | US20040266884 Compounds for blocking androgen receptors |
| 12/30/2004 | US20040266882 Administering chemotherapeutically effective amount of at least one chemotherapeutic agent and a chemosensitizing effective amount of at least one 3-aryloxy-3-phenylpropylamine such as 3-(p-isopropoxyphenoxy)-3-phenylpropylamine methanesulfonate; advantageous in treatment of multidrug resistance cancer |
| 12/30/2004 | US20040266871 Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons |
| 12/30/2004 | US20040266870 Inhibitors of the chemotactic activation induced by the fraction C5a of complement and from other chemotactic proteins (chemokines) that y activate a 7-transmembrane-domain receptor; psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, fibrosis; antiischemic agents |
| 12/30/2004 | US20040266869 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides |
| 12/30/2004 | US20040266867 2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert-butylaminoethanol hydrochloride; treating asthma and bronchitis |
| 12/30/2004 | US20040266861 Administering a therapeutically effective amount of a compound which is a cannabinoid receptor agonist, a pharmaceutically acceptable salt of the compound, an isomer of the compound, or a pharmaceutically acceptable salt of the isomer |
| 12/30/2004 | US20040266855 Effective against Src family; cancer, osteoporosis |
| 12/30/2004 | US20040266842 Thiazolyl substituted triazoles as alk5 inhibitors |
| 12/30/2004 | US20040266841 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 12/30/2004 | US20040266839 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors |
| 12/30/2004 | US20040266835 Inhibitors against complex II of electron transport system |
| 12/30/2004 | US20040266830 Insulin sensitivity enhancer and second antidiabetic of different mechanism; suppressing hyperglycemia |
| 12/30/2004 | US20040266826 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors |
| 12/30/2004 | US20040266822 Secondary amines; tissue specificity; reduced side effects; cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasms, ischemia, anoxic nerve injury |
| 12/30/2004 | US20040266816 Potent and long lasting antimuscarinic agents; respiratory, urological or gastrointestinal disorders |
| 12/30/2004 | US20040266801 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 12/30/2004 | US20040266800 a selective N-alkylation reaction by adding a base; hydrolysing and amidating; useful for treating cardiovascular diseases caused by binding angiotensin II to its receptors, through antagonistic activity against angiotensin II receptors |
| 12/30/2004 | US20040266799 Corticotropin-releasing factor (CRF); such as 4-chloro-2-methyl-5-nitro-8-(2,4-dichloro)phenyl-1,7-naphthyridine for treating stroke, anxiety, depression, and/or irritable bowel syndrome |
| 12/30/2004 | US20040266797 Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis |
| 12/30/2004 | US20040266782 Cyclic amine derivatives-CCR-3 receptor antagonists |
| 12/30/2004 | US20040266780 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 12/30/2004 | US20040266778 Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
| 12/30/2004 | US20040266775 for human, veterinary, or phytoprotective use, e.g., inhibiting the cellular sodium-proton antiporter activity, for the treatment of cardiovascular diseases, metabolic diseases, cancerous diseases or fibrotic diseases |
| 12/30/2004 | US20040266771 Use of tyrosine kinase inhibitors for treating bone loss |
| 12/30/2004 | US20040266766 Selective urokinase inhibitors |
| 12/30/2004 | US20040266765 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 12/30/2004 | US20040266764 Hydroxamic acid derivatives |
| 12/30/2004 | US20040266759 Possess antithrombotic and anticoagulant properties; example compound: 1-(5-Chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl]piperazine |
| 12/30/2004 | US20040266757 4-(Oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]-nonane derivatives, preparation and therapeutic use thereof |
| 12/30/2004 | US20040266750 Beta-lactamyl vasopressin v1aantagonists |
| 12/30/2004 | US20040266746 the sensitivity of cells typical of various proliferative disorders to the ansamycin CNF-101 ("17-AAG") is proportional to the HER-2 levels in those cells |
| 12/30/2004 | US20040266736 Particularly preferred inhibitors are low molecular weight substances unable to cross the blood/brain barrier, and act systemically and not centrally |
| 12/30/2004 | US20040266733 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) |
| 12/30/2004 | US20040266726 yeast-derived ingredient having beta 1,3/1.6 glucan structure (IMMUTOL) or Norwegian Beta Glucan (TM); natural killer cell activating capabilities and tumor angiogenesis inhibiting capability by oral administration |
| 12/30/2004 | US20040266723 Antiviral agents for treatment of Flaviviridae infections |
| 12/30/2004 | US20040266720 Splice-region antisense composition and method |
| 12/30/2004 | US20040266698 Pyrane derivatives as both ace-and nep-inhibitors |